All In Biotech

Drug Trial Radar · NCT07489612

QLS1410 in Participants With Uncontrolled Hypertension

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

260

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Conditions

  • Hypertension (HTN)

Interventions

  • Dose 1 of QLS1410Drug

    QLS1410 tablet administered orally, once daily (QD).

  • Dose 2 of QLS1410Drug

    QLS1410 tablet administered orally, once daily (QD).

  • Dose 3 of QLS1410Drug

    QLS1410 tablet administered orally, once daily (QD).

  • placeboDrug

    Matching placebo tablet administered orally, once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean seated systolic blood pressure (SBP) at week 12Time frame: At week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.